Recruitment of liver sinusoidal endothelial cell progenitor cells (sprocs) from the bone marrow by vascular endothelial growth factor-stromal cell-derived factor-1 (VEGF-sdf-1) signaling promotes recovery from injury and drives liver regeneration. Matrix metalloproteinases (MMPs) can proteolytically cleave VEGF, which might inhibit progenitor cell recruitment, but systemic matrix metalloproteinase inhibition might prevent efflux of progenitors from the bone marrow. The hypothesis for this study was that liver-selective MMP-9 inhibition would protect the hepatic VEGF-sdf-1 signaling pathway, enhance bone marrow sproc recruitment, and thereby ameliorate liver injury and accelerate liver regeneration, whereas systemic MMP inhibition would impair bone marrow sproc mobilization and therefore have less benefit or be detrimental. We found that liver-selective MMP-9 inhibition accelerated liver regeneration after partial hepatectomy by 40%, whereas systemic MMP inhibition impaired liver regeneration. Liver-selective MMP-9 inhibition largely abolished warm ischemia-reperfusion injury. In the extended hepatectomy model, liver-selective MMP-9 inhibition restored liver sinusoidal endothelial cell integrity, enhanced liver regeneration, and reduced ascites. Liverselective MMP-9 inhibition markedly increased recruitment and engraftment of bone marrow sprocs, whereas systemic MMP inhibition impaired mobilization of bone marrow sprocs and their hepatic engraftment. Hepatic MMP-9 proteolytically cleaved VEGF after partial hepatectomy. Liver-selective MMP-9 inhibition prevented VEGF cleavage and doubled protein expression of VEGF and its downstream signaling partner sdf-1. In contrast, systemic MMP inhibition enhanced recruitment and engraftment of infused allogeneic progenitors. Conclusion: Liver-selective MMP inhibition prevents proteolytic cleavage of hepatic VEGF, which enhances recruitment and engraftment of bone marrow sprocs after liver injury. This ameliorates injury and accelerates liver regeneration. Liver-selective MMP-9 inhibition may be a therapeutic tool for liver injury that damages the vasculature, whereas systemic MMP inhibition can enhance the benefit of stem cell therapy with endothelial progenitor cells. (Hepatology 2019;69:314-328).
A fter various forms of liver injury, hepatic vascular endothelial growth factor (VEGF) is the central mediator that signals through stromal cell-derived factor-1 (sdf-1 or CXCL12) to induce proliferation in the bone marrow, mobilization to the circulation, and engraftment in the liver of CXCR7+ liver sinusoidal endothelial cell progenitor cells (sprocs) and signals through the nitric oxide pathway to induce the differentiation of engrafted sprocs to fenestrated liver sinusoidal endothelial cells (LSECs). (1) (2) (3) Although there is ample evidence that LSECs drive liver regeneration, (4) (5) (6) our group has shown that this function is fulfilled by engrafted bone marrow (BM) sprocs amongst the LSECs. Bone marrow suppression impairs liver regeneration after partial hepatectomy, and the effect of bone marrow suppression is fully offset by infusion of whole bone marrow or of sprocs. (1) (2) (3) Only the CXCR7+ subset of circulating sprocs engrafts in the liver, (1) and knockout of CXCR7+ endothelial cells in the body impairs liver regeneration. (7) In addition to driving liver regeneration, recruitment of BM sprocs promotes recovery from toxic injury. (2, 8) There are 2 reasons to assume sprocs are a subset of endothelial progenitor cells. First, after partial hepatectomy, there is a 2-fold increase in circulating sprocs that persists for 72 hours.
(3) At 6 hours after partial hepatectomy, upwards of 90% of these cells are the CXCR7 + fraction that engrafts in the liver, (1) but from 24 to 72 hours, the circulating endothelial progenitor cells are almost all CXCR7 -. Second, LSECs are CD31+ (a classic endothelial marker) and CD45+, (8, 9) and we therefore define sprocs as progenitor cells with both these markers. Endothelial progenitor cells are often defined as the CD45-fraction of circulating progenitor cells. This further supports that LSEC progenitor cells or sprocs are a subset of endothelial progenitor cells.
Disparate types of injury that target LSECs increase matrix metalloproteinase (MMP) activity, including cold preservation injury, (10) sinusoidal obstruction syndrome, (11) acetaminophen toxicity, (12) ischemia-reperfusion injury, (13, 14) and small-for-size syndrome. (15) The literature has conflicting reports on whether MMPs enhance (16) (17) (18) or reduce (19) VEGF effects. An explanation for MMP-mediated reduction of VEGF activity is the finding that MMPs, including MMP-9, can proteolytically cleave VEGF 164 , (19) generating VEGF with a dysfunctional angiogenic response. This suggests that inhibition of hepatic MMP activity after liver injury might enhance VEGF-sdf-1 recruitment and repair by BM sprocs. Conversely, proteolytic cleavage by MMPs, including MMP-9, of extracellular matrix and cytokines that retain stem cells in their niche is necessary for mobilization of BM stem cells. (20, 21) Thus, inhibition of hepatic MMP activity might improve BM sproc recruitment and engraftment in the liver, whereas inhibition of BM MMP should impair BM sproc mobilization and diminish repair of liver injury.
Based on the above, we formulated the following 2 hypotheses:
1. Liver-selective inhibition of MMP with sparing of BM MMP should reduce liver injury and promote liver regeneration, whereas systemic MMP inhibition should be less beneficial or even detrimental. 2. Engraftment of infused sprocs for stem cell therapy should benefit from systemic MMP inhibition by preventing proteolytic cleavage of hepatic VEGF and by reducing release of sprocs from the BM, thereby decreasing competition for engraftment.
The therapeutic benefit of liver-selective MMP-9 inhibition is shown in models of two-thirds partial hepatectomy (PH) (Figs. 1 and 2 ), ischemia-reperfusion injury (Fig. 3) , and 90% hepatectomy as a model of small-for-size syndrome (Fig. 4) . Examination of the mechanisms by which liver-selective MMP-9 inhibition protects against injury and promotes liver regeneration are shown in Figs. 5 and 6. The use of systemic MMP inhibition to promote engraftment of infused sprocs, as a model for stem cell therapy, is shown in Fig. 7 . Figure 8 is a diagram that describes the molecular pathways underlying the mechanisms.
Materials and Methods

ReageNtS
Chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless stated otherwise. All antibodies and dilutions used are listed in Supporting Table S1 .
aNIMal StUDIeS
Lewis rats were obtained from Harlan (Placentia, CA). Breeding pairs of Lew-Tg(CAG-EGFP)ys rats were obtained from the National Institutes of Health Rat Resource and Research Center at the University of Missouri. Male rats were used for the experiments. Rats were kept in conventional housing for rats, consisting of Allentown polycarbonate rat cages with filter tops and Sani-Chips bedding (wood product), in a 12:12-hour light-dark cycle (lights on from 6 AM to 6 PM) at room temperature (21-23°C), with 5-μm-filtered water delivered to cages via an Edstrom automatic watering valve. Purina Lab Diet 5001 and water were provided ad libitum. Rats that showed distress postoperatively, based on activity level, behavior, appearance, reduced intake of food or water, or respiratory distress, were euthanized.
All protocols were reviewed and approved by the Animal Care and Use Committee at the University of Southern California to ensure ethical and humane treatment of the animals. This study followed the guidelines outlined in the Office of Laboratory Animal Welfare's Public Health Service Policy on Humane Care and Use of Laboratory Animals (2015).
paRtIal HepateCtoMy
Partial (70%) hepatectomy was performed under general anesthesia with ketamine-xylazine (80-90 mg/ kg i.p.). For 70% partial hepatectomy, the median and left lateral lobes were removed. Buprenorphine SR (1 mg/kg) was used postoperatively for analgesia.
eXteNDeD HepateCtoMy
To achieve 90% hepatectomy, the medial and left lateral and the superior and inferior portion of the right lobe were resected with preservation only of the caudate lobe. To prevent postoperative hypoglycemia, animals were gavaged once with 0.5 ml 20% glucose, and for the first 16 hours 20% glucose was provided as oral hydration through a liquid diet feeding tube (Bioserv cat 9010) that was positioned so rats could drink without significant exertion, followed by free access to water. Rats received standard laboratory chow ad libitum. All rats survived until they were euthanized on day 2.
ISCHeMIa-RepeRFUSIoN MoDel
Ischemia was induced by clamping the vessels in the hilum that perfuse the medial and left lateral lobes with a nontraumatic microvascular clip. After 1 hour, the microvascular clip was released. The abdomen was closed and the rats were left to recover with free access to standard chow diet and water ad libitum. Preliminary studies established that alanine aminotransferase (ALT) and aspartate aminotransferase (AST) peaked at 6 hours.
BoNe MaRRoW tRaNSplaNtatIoN
BM cells were obtained from one tibia and femur from the donor. Recipients underwent 1,000 cGy total body irradiation and were injected via tail vein with 50 million BM cells. Rats received oxytetracycline (200 mg/ml) diluted 1:1,000 in the drinking water starting 2 days before irradiation and continuing until 1 week after irradiation. BM was allowed to engraft for 2 months before use. BM from Lew-Tg(CAG-EGFP)ys Lewis rats was transplanted into wild-type Lewis rats, and cells were tracked by green fluorescent protein (GFP) expression.
lIVeR-SeleCtIVe MMp-9 INHIBItIoN
Knockdown of MMP-9 was achieved by injection of 1 of 2 MMP-9 antisense oligonucleotides that were a kind gift from Ionis Pharmaceuticals (Ionis No 283953 and 283973, Carlsbad, CA; Supporting Table S2 ), 20 mg/kg intraperitoneally twice weekly for 4 weeks.
Hepatic MMP-2/9 inhibition in other studies was performed by infusing 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid (Abcam, Cambridge, MA), 100 µg/h, into the portal circulation by an Alzet mini-osmotic pump (model 2ML1; Alza Corporation, Palo Alto, CA) via a cannula inserted into the inferior mesenteric vein starting 2 days before the relevant study.
SySteMIC MMp INHIBItIoN
Doxycycline (Sigma, St. Louis, MO), 15 mg/ kg i.g., was given twice daily starting 2 days before the relevant study. Control studies were performed with the same dose of a chemically modified tetracycline, isochlorotetracycline, which is only a weak MMP inhibitor. In other experiments, MMP-2/9 was inhibited by infusing 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid, 100 µg/kg/h, intraperitoneally with an Alzet mini-osmotic pump (model 2001, Durect Corporation, Cupertino CA).
FIg. 2.
Liver-selective MMP-9 inhibition accelerates liver regeneration after two-thirds PH. (A) Time course from day 3 to day 7. Pretreatment with MMP-9 ASO accelerates liver regeneration after PH compared to scrambled control ASO (n = 3). The dotted line is the average liver-to-body-weight ratio of untreated control littermates. (B) Percentage of proliferating hepatocytes and nonparenchymal cells in the sinusoids on day 2 (ki-67) (n = 3). (C) The number of hepatocytes proliferating in each zone from day 2 to day 6 is shown for control ASO and MMP-9 ASO pretreated prior to PH (n = 3 for each day). (D) The number of nonparenchymal cells proliferating in each zone from day 2 to day 6 is shown for control ASO and MMP-9 ASO pretreated prior to PH (n = 3 for each day). (E) Hepatocyte proliferation (ki-67) on day 2 after PH is enhanced by liver-selective MMP inhibition with MMP-9 ASO or by intraportal MMPi compared to intraperitoneal MMPi, whereas systemic inhibition with doxycycline reduces hepatocyte proliferation (n = 3). (F) MMP-9 ASO increases liver-to-body-weight ratio by 27% on day 5 after PH, whereas doxycycline reduces liver-to-body-weight ratio by 29% (n = 3). A slash (/) indicates 2 treatments, e.g., MMP ASO/PH is MMP ASO plus partial hepatectomy. Analysis by ANOVA was statistically significant and analyzed post hoc by Fisher's least significant difference. Levels of statistical significance are * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Unless otherwise indicated, significance is based on comparison with the appropriate control. Unprocessed original scans of blots are shown in Supporting Fig. S2B and 2C. Abbreviations: Ct, control; Dox, doxycycline; MMPi, inhibitor of MMP 2 and 9; PH, partial hepatectomy; PP, periportal, ML, midlobular, CL, centrilobular. 
lSeC ISolatIoN
LSECs were isolated by collagenase perfusion, iodixanol density gradient centrifugation, and centrifugal elutriation, as previously described. (22, 23) Yields averaged 86×10 6 cells per normal rat liver (range 69-95 × 10 6 ) with average viability of 94% (range 91%-96%). Purity of the cells was 99%, as determined by uptake of formaldehyde-treated serum albumin (kind gift from Bård Smedsrod, University of Trømso, Trømso, Norway), a function specific to LSECs. Cells isolated by this protocol have an appropriate range of fenestrae organized in sieve plates.
SpRoC ISolatIoN
BM and circulating sprocs were isolated by immunomagnetic selection for CD133 using a CD133 Cell Isolation Kit (Miltenyi Biotec, Auburn, CA) and separation with an autoMACS Pro (Miltenyi Biotec, Auburn, CA), followed by fluorescence-activated cell sorting for CD45 and CD31 (Supporting Fig. S1 ).
To isolate resident sprocs, LSECs were isolated as described above, and the CD133+ fraction was obtained by immunomagnetic selection. (3) To determine the number of sprocs in the circulation and BM from Lewis rats 6 hours after partial hepatectomy, CD133+ cells were isolated by immunomagnetic selection for CD133 from peripheral blood or BM. Cell suspensions were preblocked with FcR blocking reagent and incubated for 60 minutes with antibodies to rat CD45 and CD31. CD133+45+31+ cells were quantified by flow cytometry. In some experiments, cells were also stained with antibody to rat CXCR7, to identify CD133+45+31+CXCR7+ cells in the circulation. 
FloW CytoMetRy
Flow cytometry was performed using a FACSCalibur (BD Biosciences). Isotype control antibodies were used to determine appropriate gates, voltages, and compensation required for multivariate flow cytometry. Cell Quest Pro software was used for analysis.
IMMUNoHIStoCHeMIStRy FoR KI-67
Deparaffinized 5-µm sections of liver were treated with Bond ER-2 antigen retrieval (Leica Biosystems, Buffalo Grove, IL) for 20 minutes. After preblocking for 10 minutes with Rodent Block R (Cat#RBR962G, Biocare, Pacheco, CA), sections were incubated with antibody against Ki-67 for 60 minutes. Immunohistochemistry was performed by incubating sections with rabbit-on-rodent HRPPolymer (cat # RMR622G, Biocare) for 30 minutes. Slides were rinsed in Bond diaminobenzidine (Leica Biosystems) for 10 minutes. After counterstaining with Bond hematoxylin, slides were dehydrated and covered using a coverslip with resinous mounting medium (Leica Biosystems).
Ki-67 positive cells were determined using photographs taken with a 20x-objective in 15 lobules per (B) MMP-9 ASO increases and systemic doxycycline decreases BM sproc mobilization to the circulation (n = 3). (C) The number of circulating CXCR7+ sprocs are increased by liver-selective MMP inhibition (MMP-9 ASO or intraportal infusion of an MMP2/9 inhibitor) but reduced by systemic MMP inhibition (doxycycline or intraperitoneal MMP2/9 inhibitor) (n = 3). (D) Hepatic engraftment after PH is enhanced by liver-selective MMP inhibition (MMP-9 ASO or intraportal MMP2/9 inhibitor) but reduced by systemic MMP inhibition (doxycycline or intraperitoneal MMP2/9 inhibitor) (n = 3). Panels A-C are at 6-hour time points; engraftment in panel D was determined at 24 hours. Analysis by ANOVA was statistically significant and analyzed post hoc by Fisher's least significant difference. Levels of statistical significance are * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Unless otherwise indicated, significance is based on comparison with the appropriate control. rat, n = 3. To assess the percentage of proliferating hepatocytes and nonparenchymal cells, slides were coded and the percentage of Ki-67 positive cells was determined blindly by X.W. To determine zonation of proliferating cells, each lobule was divided into 3 even fields, and the total number of ki-67 positive cells/ field was counted. 
SeRUM alt aND aSt MeaSUReMeNtS
CD31 StaININg
Frozen sections of liver were fixed in cold acetone and stained with a mouse monoclonal anti-CD31 and m-IgGκ BP-FITC anti-mouse IgG. Slides were examined using a Nikon PCM-2000 confocal microscope with a 488-nm laser excitation wavelength.
IMMUNoBlottINg
Samples from freshly isolated liver were harvested using triple lysis buffer (50 mM Tris base, 150 mM 164 , with an increase after PH that is blocked by MMP-9 ASO pretreatment; and (C,D) VEGF 164 and sdf-1, with an increase after PH that is further increased after MMP-9 ASO pretreatment. Analysis by ANOVA was statistically significant and analyzed post hoc by Fisher's least significant difference. Levels of statistical significance are * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Unprocessed original scans of blots are shown in Supporting Fig. S6 . NaCl, 3 mM sodium azide, 12 mM sodium deoxycholate, 0.1% SDS, 1% Nonidet-P40) supplemented with 2 mM phenylmethylsulphonyl fluoride, 1 mM sodium orthovanadate, and 1% protease inhibitors cocktail (Santa Cruz sc-24948). Proteins were purified by centrifugation at 15,000 g at 4˚C for 10 minutes and quantified using DC™ Protein Assay Kit (BioRad). The samples obtained from BM extracellular fluid were preserved in PBS. For MMP-9 analysis, 100 μg of total protein was used from each sample per lane and resolved on NuPAGE™ Novex™ 10% Bis-Tris Protein Gels using MOPS running buffer. Proteins were transferred onto 0.45 μm nitrocellulose membranes via electroblotting using XCell II™ Blot Module (Invitrogen) for 1 hour at 30 V. For SDF-1 and VEGF analysis, 75 μg of total protein was used from each sample per lane and resolved on NuPAGE™ Novex™ 4%-12% Bis-Tris Protein Gels using MES running buffer. Proteins were transferred onto 0.2 μm nitrocellulose membranes via electroblotting using Transblot SD Semi-Dry Transfer Cell™ (Bio-rad) for 20 minutes at 25 V. Membranes were blocked using NAP-BLOCKER™. Blots were probed with primary antibody overnight followed by IRDye secondary antibodies. Membrane digital images were acquired with the Odyssey Infrared Imaging System (LI-COR) and analyzed using the LI-COR Image Studio™. Analyses were performed in triplicate and normalized by GAPDH or ß-actin values.
StatIStICal aNalySIS
Unless stated otherwise, statistical analysis was performed by ANOVA and, if the ANOVA was statistically significant, analyzed post-hoc by Fisher's least significant difference using Graphpad Prism. Levels of statistical significance are * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Unless otherwise indicated, statistical significance is compared to the appropriate control. All experiments were performed with n = 3 unless otherwise stated.
Results
aCCeleRatIoN oF lIVeR RegeNeRatIoN
Pro-MMP-9 is stored in granules in cells, and its proteolytic activity occurs extracellularly after degranulation and cleavage to MMP-9. In normal liver, LSECs are a major source of MMP-9 (Supporting Fig. S2A ) which is consistent with the LSEC as the liver cell with the highest MMP-9 activity. (11) PH increased MMP-9 expression in the liver, and MMP-9 antisense oligonucleotides (ASO) abrogated the increase (Fig. 1A,B and Supporting Fig.  S2B ). Liver selectivity of the ASO was confirmed by measuring MMP-9 activity in the extracellular fluid of the BM. BM MMP-9 activity was increased after PH, but MMP-9 ASO pretreatment did not alter BM MMP-9 activity (Fig. 1C,D and Supporting Fig.  S2C) . Figure 2A is a key panel. MMP-9 ASO accelerated liver regeneration by 40%; to the best of our knowledge, this degree of acceleration is unprecedented. A time course of liver-to-body-weight from day 3 to day 7 after PH demonstrates that the liver-to-bodyweight ratio reaches that of control littermates by day 4 after MMP-9 ASO pretreatment compared to day 7 in the control-ASO pretreated group. MMP-9 ASO pretreatment increased proliferation of hepatocytes and nonparenchymal cells by 80% on day 2 (Fig. 2B) . Hepatocyte proliferation in the MMP-9 ASO group is higher in all 3 zones of the liver on day 2 and higher in the periportal and midlobular region on day 3 (Fig.  2C) . For nonparenchymal cells from rats treated with MMP-9 ASO, proliferation is higher in all 3 zones on days 2 and 3, and proliferation is higher in the midlobular region on days 4 and 5 (Fig. 2D) . Liver-selective FIg. 7 . Model of stem cell therapy. Systemic MMP inhibition with doxycycline followed by PH and infusion of GFP+ allogeneic sprocs. Doxycycline enhances engraftment of infused sprocs, expressed as the percentage of GFP+ LSECs 2 days and 3 months later (n = 3). **** P < 0.0001 and * P < 0.05 compared to control by unpaired t test.
MMP-9 inhibition with either MMP-9 ASO or intraportal MMP-2/9 inhibitor enhances hepatocyte proliferation on day 2 compared to their respective controls, whereas systemic MMP inhibition with doxycycline, which inhibits several MMPs, including MMP-9, (24, 25) reduces hepatocyte proliferation compared to its solvent control (Fig. 2E) . Of note, neither doxycycline nor intraportal MMP-2/9 inhibitor given to controls was hepatotoxic (Supporting Fig. S3A) .
Comparison of liver-selective versus systemic MMP inhibition demonstrates that liver-to-bodyweight ratio on day 5 is increased in the MMP-9 ASO pretreatment group by 27% compared to control ASO pretreatment (Fig. 2F) . Systemic MMP inhibition with doxycycline reduces liver-to-body-weight ratio on day 5 by 29% compared to its solvent control (Fig. 2F) . To rule out the possibility that liver-selective MMP inhibition recruited a stem cell for one of the other liver cell types, livers were digested on day 2 after PH and examined by flow cytometry. At least 94% of CD133+ cells were CD31+ cells, i.e., endothelial cells (Supporting Fig. S3B ).
pReVeNtIoN oF ISCHeMIa/ RepeRFUSIoN (I/R) INJURy
Induction of ischemia for 1 hour, followed by 6 hours of reperfusion, led to extremely high elevations of ALT and AST (Fig 3A,B) . Pretreatment with MMP-9 ASO largely abolished injury as indicated by ALT (58 IU/l ± 10) and AST (95 IU/l ± 12) in the near-normal or modestly elevated range, respectively (Fig. 3A,B) . Histology (Fig. 3C,D) showed clearing of hepatocyte cytoplasm, lobular disarray, and absence FIg. 8. Molecular pathway diagram contrasting the effect of liver-selective and systemic MMP-9 inhibition. (A) Liver-selective MMP-9 inhibition prevents hepatic MMP-9 from proteolytically digesting hepatic VEGF after liver injury or partial hepatectomy. This allows the hepatic VEGF-sdf-1 pathway to recruit CXCR7+ sprocs from the bone marrow but does not inhibit MMP-9 activity in the bone marrow needed to mobilize sprocs. (B) Systemic inhibition of MMP prevents proteolytic cleavage of VEGF by hepatic MMP-9, thus preserving the VEGF-sdf-1 pathway, but prevents sprocs from leaving the bone marrow by inhibiting the bone marrow MMP activity needed for release of the sprocs. The net effect is to reduce circulating sprocs and impair recruitment of sprocs to the liver.
of LSECs in the control-ASO/I/R injury group (left panels of Fig. 3C,D) , whereas the MMP-9 ASO/ I/R injury group showed preservation of hepatocyte integrity and presence of LSECs (right panels of Fig. 3C,D) . The findings suggest that the predominant injury at 6 hours was to LSECs rather than to hepatocytes; LSECs were largely absent in the control ASO pretreated group (Fig. 3C) , but there was only clearing of cytoplasm and no frank necrosis of hepatocytes. Thus, pretreatment by MMP-9 ASO prevented subsequent hepatocyte necrosis by promoting repair of the LSEC lining.
atteNUatIoN oF SMall-FoRSIZe SyNDRoMe
In living-donor related transplantation or after extensive liver resection for metastases, the recipient's existing portal vein flow does not adapt to the small liver. Damage to the liver graft or remnant is thought to be due to hyperperfusion, and the injury is known as small-for-size syndrome. Extended hepatectomy, or removal of 90% of the liver, is a model for small-forsize syndrome. On day 2 after extended hepatectomy, CD31 staining demonstrated a marked absence of LSECs lining the sinusoids (Fig. 4A, middle panel) , which is consistent with the collapse of sinusoids seen during the first 72 hours after PH. (26) In contrast, the sinusoids of rats pretreated with MMP-9 ASO followed by extended hepatectomy (Fig. 4A , right panel) had LSEC lining that appears comparable to the untreated control livers (Fig. 4A, left panel) . The 3 panels of Fig. 4A are centered on the pericentral lobule for the sake of comparison, but the respective changes in LSEC lining in the pericentral lobule were representative of the whole liver (data not shown). Pretreatment with MMP-9 ASO also reduced ascites on day 2 by 57% compared to control ASO pretreatment (Fig. 4C) , likely due to patent sinusoids that improved liver hemodynamics.
INCReaSeD ReCRUItMeNt aND eNgRaFtMeNt oF BM SpRoCS
To examine the mechanism of the therapeutic benefit of liver-selective MMP inhibition, the respective effects of liver-selective and systemic MMP inhibition on BM sproc recruitment and engraftment were examined in the PH model. MMP-9-ASO/PH increased the number of sprocs in the BM compared to control ASO/PH (Fig. 5A) . Systemic MMP inhibition in the doxycycline/PH group increased the number of sprocs in the BM significantly more than MMP-ASO/PH, consistent with impairment of sproc release by MMP inhibition of the BM.
Mobilization
MMP-9-ASO/PH increased BM sproc mobilization to the circulation compared to ASO control/PH by 180%, whereas doxycycline/PH reduced mobilization of BM sprocs by 72% (Fig. 5B) . This is consistent with the hypothesis that liver-selective MMP-9 inhibition protects the chemoattractant signaling to BM sprocs and promotes recruitment of sprocs from the BM, whereas systemic MMP inhibition prevents release of sprocs from the BM. BM sprocs that engraft in the liver are CXCR7+, (1) so addition of this marker is a closer approximation of actual sprocs, i.e., LSEC-specific endothelial progenitor cells, in the circulation. Liver-selective MMP inhibition with either MMP-9-ASO or with slow infusion into the portal circulation (intraportal infusion) of an MMP-2/9 inhibitor, (2R)-2-[(4-Biphenylylsulfonyl)amino]-3-phenylpropionic acid, increased CXCR7+ sprocs in the circulation by 260% and 110%, respectively, after PH, whereas systemic MMP inhibition with either doxycycline or intraperitoneal injection of the MMP-2/9 inhibitor reduced the number of CXCR7+ sprocs mobilized to the circulation by 90% and 86%, respectively (Fig.  5C ). Pharmacological inhibition with the MMP-2/9 inhibitor abrogated the increase in hepatic MMP-9 expression when given either liver-selectively by intraportal infusion or intraperitoneally (Fig. 1A) .
engraftment
To track BM sproc engraftment in the liver, wildtype rats underwent BM transplantation with BM from transgenic EGFP+ rats. Liver-selective MMP inhibition with either MMP-9 ASO/PH or intraportal MMP-2/9 inhibitor/PH increased hepatic engraftment of GFP+ BM sprocs by 134% and 45%, respectively, whereas systemic inhibition with either doxycycline/PH or intraperitoneal MMP-2/9 inhibition/PH reduced hepatic engraftment of BM sprocs by 58% and 36%, respectively, compared to control/ PH (Fig. 5D) . As a control, the effect of a different MMP-9 ASO on engraftment was examined, and this had near-identical effect on engraftment to the MMP-ASO described above (Supporting Fig. S4 ). To confirm that the effect of doxycycline was due to MMP inhibition rather than an antibiotic effect, isochlorotetracycline was administered prior to PH. Isochlorotetracycline had no effect on engraftment (Supporting Fig. S5 ).
MeCHaNISM oF lIVeRSeleCtIVe MMp INHIBItIoN
Upregulation of MMP-9 expression after PH (Fig.  1A, B ) (27) was accompanied by increased expression of a 17 kDa VEGF cleavage fragment (Fig. 6A,B) , which is consistent with previous reports of MMP-9 producing a VEGF 164 cleavage product that has dysfunctional angiogenic properties. (19, 28) Pretreatment with MMP-9 ASO completely prevented increased expression of the 17 kDa cleavage product after PH and led to significantly higher hepatic VEGF 164 and sdf-1 in the MMP-9 ASO/PH group compared to the ASO Ct/ PH group (Fig. 6A-D, Supporting Fig. S6 ). MMPs, including MMP-9, can also cleave sdf-1, leading to decreased chemoattraction. We observed faint expression of a 13 kDa band of sdf-1 that increased after PH, but MMP-9 ASO pretreatment did not diminish the size of the 13 kDa band (data not shown).
INCReaSeD eNgRaFtMeNt oF INFUSeD SteM CellS
Stem cell therapy with infused cells requires engraftment. However, progenitor cells that are infused after injury compete with BM progenitors. Indeed, infusion of EGFP+ sprocs 6 hours after PH resulted in only 0.7% of LSECs derived from the infused sprocs on day 2 and 1.5% by 3 months (Fig. 7) . Systemic inhibition of MMP with doxycycline, which reduces mobilization of BM sprocs (see above), increased engraftment of infused sprocs 7-fold by day 2 after infusion and almost 10-fold by 3 months (Fig. 7) .
Discussion
Liver-selective MMP inhibition accelerated liver regeneration after two-thirds PH by 40%, largely abolished I/R injury, and accelerated liver regeneration and reduced ascite formation after extended hepatectomy. The mechanism led to inhibition of proteolytic cleavage by MMP-9 of VEGF 164 , which resulted in increased expression of VEGF 164 and the downstream chemokine sdf-1. The VEGFsdf-1 pathway recruited BM endothelial progenitor cells of the LSECs, so-called BM sprocs, that are essential for liver regeneration. (1, 2) In contrast, systemic MMP inhibition impaired recruitment of BM sprocs to the liver and reduced liver regeneration after PH by preventing mobilization of BM progenitor cells to the circulation. Consistent with this, systemic pharmacological inhibition of MMPs has been studied in liver injury models, but often with modest benefit. (12, 13, 29, 30) Figure 8 summarizes the findings described above.
Previous studies have demonstrated MMP-9 activity in LSECs but undetectable activity in hepatocytes, Kupffer cells, or hepatic stellate cells. (11) Although antisense oligonucleotides have been designed that are more hepatocyte specific, the 2′-methoxyethyl ASOs used in the current study target both hepatocytes and nonparenchymal cells. Thus, LSECs are the likely target of the MMP ASO used in the current study.
The findings reported here have translational implications for the liver. MMP inhibitors failed clinical trials to treat cancer, but good candidate drugs reportedly have no toxicity with short-term administration. Treatment of a cadaveric organ donor with systemic MMP inhibition might protect multiple organs from ischemia-reperfusion injury without inhibiting MMP in the recipients' BM. Serendipitous application of liver-selective MMP-2/9 inhibition completely prevented severe toxin-induced sinusoidal obstruction syndrome. (11) The extended hepatectomy studies presented here suggest that liver-specific MMP inhibition would attenuate small-for-size syndrome. For living-related liver donor transplantation and for extended hepatectomy for liver tumors, MMP-9 inhibition would need to be strictly liver-specific to prevent MMP inhibition of the BM.
The basic mechanistic processes described here in liver injury mimic those found in other organs. MMPs increase after injury in several organs, including the heart, (31, 32) brain, (33, 34) lung, (35, 36) kidneys, (33, 37) pancreas, (38) and vascular wall. (39) VEGF and sdf-1 signaling recruit endothelial progenitor cells to the heart, (40, 41) brain and spine, (42) (43) (44) lungs, (45) kidneys, (46) peripheral nerves, (47) bone, (48, 49) and limbs. (50) Thus, the benefit of end-organ-specific MMP inhibition is likely applicable to other organs and should apply to recovery from insults that injure the vasculature. The challenge will be to develop end-organ-specific delivery of an MMP inhibitor, given the observation that systemic inhibition that inhibits BM MMP is detrimental. Slow infusion of an MMP inhibitor into a specific organ may be an option if (near)-complete uptake of the MMP inhibitor by the organ can be achieved.
Stem cell therapy with infused cells requires engraftment, and the current study demonstrates that engraftment of infused endothelial progenitor cells after injury is markedly increased by systemic MMP inhibition. One could envision that one application of this would be enhanced engraftment of endothelial progenitor cells that are gene-edited to be anticoagulant to reduce the risk of recurrent thrombosis or vascular occlusion in a compromised vascular bed.
